| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
FDA Commissioner Stephen Hahn said Monday that, by the end of the week, U.S. labs would have enough materials to perform close to 1 million tests. Public health experts say that figure is misleading because it is far larger than the number of samples that can be processed in labs in the coming weeks.[CR-LF][CR-LF]The realistic estimate is now likely around 5,000 each day, according to a public health lab industry group.
With legal marijuana use laws continuing to make traction throughout the U.S., and the perception of a dwindling job applicant pool, some employers are asking if they should continue to conduct screening for marijuana. Some employers are also challenging the entire idea of performing drug testing in their workplaces. Is there still a benefit to having a drug-free workplace program?
It could be weeks before the United States can meet the demand for coronavirus testing because doctors, hospitals and some public health labs say they aren’t set up yet to do the tests.[CR-LF][CR-LF]Ratcheting up the country’s ability to detect the disease is crucial to understand how the coronavirus — now confirmed in at least 12 states — is spreading. But testing so far has been severely limited by problems with a diagnostic test developed by CDC.
Aimed at making it a bit easier to track the ever-increasing list of coronavirus plays, here is a representative listof diagnostic companies that have either experienced recent volatility or may announce plans to develop tests for COVID-19. Some companies, of course, are more credible players than others.
Primary care physicians may be overconfident in their ability to recognize prescription drug misuse, a researcher suggested here.[CR-LF][CR-LF]An analysis that juxtaposed survey data from 500 primary care physicians with over a half million drug test results showed that nearly three-quarters of doctors trusted their patients to take medications as prescribed, but half of specimens showed signs of misuse, reported Jeffrey Gudin, MD, of Rutgers New Jersey Medical School in Newark, at the American Academy of Pain Medicine annual meeting.
A worker who is using the drug medicinally may fail a drug test and lose their job. But a recreational user could be making their workplace less safe for everyone if they come to work inebriated.[CR-LF][CR-LF]Enter workplace drug testing.[CR-LF][CR-LF]The rate of positive drug tests hit a 14 year high in 2018, according to a recent Los Angeles Times article. Of the 10 million tests processed by Quest Diagnostics, 4.4% tested positive for some type of drug.
Two years ago, the American Society for Clinical Pathology (ASCP) was presented with an opportunity to ratchet up adherence to one of its 30 recommendations — #21, which deals with evaluating adult patients with diabetes or hypertension for chronic kidney disease (CKD) through commonly used laboratory tests.[CR-LF][CR-LF]“What Choosing Wisely did was speed up the trajectory more than start the initiative,” said Lee Hilborne, MD, MPH, Past President and Chair of ASCP’s Appropriate Test Utilization Committee and Senior Medical Director for Quest Diagnostics, referring to the society’s partnership with the National Kidney Foundation to harmonize and simplify the testing protocol used to detect CKD.
Quest Diagnostics Incorporated announced that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami. Mark Guinan, Executive Vice President and CFO, will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Tuesday, March 10, 2020 at 9:30 a.m. Eastern Time.
Democratic presidential candidates' calls for "Medicare for all" may seem like a threat to profits and innovation in the U.S. healthcare sector, but not all industry executives see it that way, even in the remote chance such a proposal is enacted. Some healthcare executives say giving the public the option of government coverage could actually be a net plus for the industry by adding more customers, particularly the estimated 44 million citizens who have no coverage. For companies like Quest Diagnostics, the largest provider of lab services, the answer is to roll up the industry to give it pricing power. "There are hundreds of laboratory companies, so our acquisition strategy is to consolidate the industry," CEO Stephen Rusckowski told Mergermarket. The company expects to spend an average of $250 million to $300 million a year on acquisitions.
While staffing shortages are one of main challenges facing the lab industry, some employees are seeing a benefit in the form of rising compensation. During Quest Diagnostics' Q4 earnings call last month, CFO Mark Guinan said that the company had seen "rising wage pressure" due to the tightening labor market. Quest President, Chairman, and CEO Steve Rusckowski noted that the firm was primarily seeing this pressure at what he called "the front end of our value chain," meaning positions like couriers and specimen processing where it competes for workers not only with other labs but also with employers outside the lab industry.
UNT Health Science Center and Quest Diagnostics are collaborating to improve outcomes for high risk patients in underserved populations. Quest, which is the leading diagnostic information services company, will use its massive trove of data from its diagnostic business to provide guidance on how to manage populations effectively.
With its recent acquisition of Finnish molecular diagnostics firm Blueprint Genetics, Quest Diagnostics is looking to expand and improve its genetic testing portfolio.[CR-LF][CR-LF]The lab company was particularly interested in Blueprint's informatics capabilities, which Carrie Eglinton Manner, Quest's senior vice president of Advanced Diagnostics, said would enhance its existing genetic test offerings by improving variant interpretation and reporting.[CR-LF][CR-LF][CR-LF]"We have full next-generation sequencing services in a number of our labs," she said. "The capability that we are really excited about is their bioinformatics capability. Their bioinformatics has a depth and flexibility, including software engineering expertise, that we can apply to our entire portfolio… to help accelerate [bringing] test offerings to market as well as expanding growth for the company."
Long Island companies may have to rethink their drug testing policies as state lawmakers renew a push to legalize recreational marijuana.[CR-LF][CR-LF]A bid for legalization narrowly failed last year. Gov. Andrew M. Cuomo, who included the Cannabis Regulation and Taxation Act in his new budget, made it clear last month in his State of the State address that it's one of his top priorities. The New York State Bar Association threw its support behind legalization last month.
The human brain has a unique ability to take in information, block out unnecessary data, analyze it and issue a motor response—all within fractions of a second. It is one of the many reasons why humans are at the top of the food chain.[CR-LF][CR-LF]But the ability to process information, make a quick decision and act accordingly can be affected when under the influence of marijuana. All the steps involved in decision making slow down, which can—in some cases—cause catastrophic, unintended effects.
Mayor Erin Stewart held a ribbon cutting ceremony Monday afternoon for Quest Diagnostics’ newest Patient Service Center at One Grove Place.
Quest Diagnostics, a leading provider of diagnostic information services, and Memorial Hermann Health System, a leading not-for-profit health system that includes 17 hospitals and more than 300 care delivery sites in the Greater Houston region, announced a multi-pronged, long-term collaboration intended to broaden access to innovative, high-value laboratory services for providers and patients in Greater Houston.[CR-LF][CR-LF]Quest and Memorial Hermann have executed a definitive agreement for Quest to acquire select assets which constitute substantially all the operations of Memorial Hermann Diagnostic Laboratories (MHDL), the outreach laboratory division of Memorial Hermann. The acquisition includes nearly 30 MHDL patient service centers and nearly 60 in-office laboratory service sites. These services will transition to the Quest Diagnostics full-service laboratory in Houston. Upon closing, Quest will also provide professional laboratory management services through a multi-year agreement for all of Memorial Hermann's 21 hospital laboratories, which provide onsite rapid response testing. Memorial Hermann will continue to wholly own these labs.
Quest Diagnostics today reported a 5 percent year-over-year rise in revenues for the fourth quarter, beating the consensus expectation from Wall Street analysts.[CR-LF][CR-LF]Revenue for the three months ended Dec. 31, 2019 was $1.93 billion, up from $1.84 billion in the same quarter last year. The consensus Wall Street estimate was $1.92 billion.[CR-LF][CR-LF]Test volumes grew 4 percent during the quarter with revenue per test growing a little more than 1 percent.[CR-LF][CR-LF]During a conference call following release of the results, Quest Chairman, President, and CEO Steve Rusckowski, said that expanded access to healthcare plan networks combined with good operational execution allowed the company to counter what he called "significant reimbursement pressure."
Companies, we all know, need to make a profit to prosper and survive. Making a buck, after all, is important to investors, employees and vendors. But over the years, executives have come to realize that they need to do much more. That is, by giving back to the communities they operate in and standing up as good neighbors and citizens.[CR-LF][CR-LF]Newsweek partnered with global data research firm Statista Inc. to publish our first ranking of America's Most Responsible Companies. As you will see from our description of the methodology, Statista worked from a universe of 2000 public companies to determine which firms were tops when it came to doing good. Quest Diagnostics is number 164.
A new study provides a look at the levels of such similarity between married partners when it comes to their heart health, in hopes of finding ways to lead more people to be like the Kellys.[CR-LF][CR-LF]Researchers examined five years of biometric measurements and blood test data from 5,364 couples. The researchers then charted how each partner measured up against seven modifiable risk factors for heart disease (smoking, exercise, diet, body mass index, blood pressure, total cholesterol and fasting glucose) and for overall cardiovascular health.
Quest Diagnostics and Memorial Hermann Health System, a leading not-for-profit health system that includes 17 hospitals and more than 300 care delivery sites in the Greater Houston region, today announced a multi-pronged, long-term collaboration intended to broaden access to innovative, high-value laboratory services for providers and patients in Greater Houston.
Doctors worry that a second drug epidemic is on the horizon, according to a recent survey. We’re still amid the opioid crisis, but 62 percent of the primary care physicians queried say it’s likely to morph into a whole new emergency, this time fueled by prescription drug misuse.[CR-LF][CR-LF]Physicians in that survey, conducted by the Center on Addiction and Quest Diagnostics, were focused on people in chronic pain who, deprived of opioids, may find relief by turning to other prescription drugs such as benzodiazepines like Valium. That’s a critical concern, but there’s another important issue that requires our urgent attention: Too many teens and young adults don’t understand that the drugs we count on to treat our medical problems can be dangerous if misused.
Quest Diagnostics today announced that it has acquired Blueprint Genetics in an all-cash equity transaction. Blueprint Genetics is a leading specialty genetic testing company with deep expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics. Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development. Financial terms of the transaction were not disclosed.
You decided to screen workers for drug use because you want to maintain a safe and productive workplace. But what should you do when workers flunk the test? Should employees be fired, given another chance or referred to an employee assistance program? Employment attorneys say consistency is the key.[CR-LF][CR-LF]"Employers should have strong policies in place addressing whether or under what circumstances they will engage in dialogue with an employee or applicant who fails a drug test," said Jill Vorobiev, an attorney with Reed Smith in Chicago. Policies also should take into account any state laws that may apply to failed drug tests and whether the employer might need to make reasonable accommodations for workers with disabilities, she said.
Twenty-three New Jersey companies have been recognized as a “Best Place to Work for LGBTQ Equality” by the Human Rights Campaign Foundation, the educational arm of the country’s largest lesbian, gay, bisexual and transgender civil rights organization.[CR-LF][CR-LF]According to the 2020 Corporate Equality Index, more than 680 companies were assessed and designated with the honor for their efforts in satisfying four criteria — non-discrimination policies, employment benefits, corporate social responsibility and responsible citizenship —earning them a score of 100%. Quest is included in this list.
Quest Diagnostics today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2020 for the sixth consecutive year.